Short-term prognosis of changes in plasma potassium following an episode of hyperkalaemia in patients with chronic heart failure.


Journal

European journal of internal medicine
ISSN: 1879-0828
Titre abrégé: Eur J Intern Med
Pays: Netherlands
ID NLM: 9003220

Informations de publication

Date de publication:
Dec 2023
Historique:
received: 11 05 2023
revised: 21 07 2023
accepted: 25 07 2023
medline: 4 12 2023
pubmed: 31 7 2023
entrez: 30 7 2023
Statut: ppublish

Résumé

There is an increasing prevalence of chronic heart failure (HF). It is well known that patients with HF and disturbances in the potassium level have an increased mortality risk. The aim of this study was to investigate the prognosis of a second plasma-potassium measurement after an episode with hyperkalaemia on short-term mortality in patients with chronic HF. From Danish national registers, 2,339 patients with chronic HF and hyperkalaemia (>4.6 mmol/L) at first potassium measurement within 14-365 days from concomitant treatment were identified. To be included, a second measurement was required within 6-30 days subsequent to the first measurement and the 60-day mortality was observed. Based on the second measurement, the patients were divided into five groups: <3.5 mmol/L (n = 257), 3.5-4.0 mmol/L (n = 709), 4.1-4.6 mmol/L (n = 1,204, reference), 4.7-5.0 mmol/L (n = 89) and >5.0 mmol/L (n = 80). To assess all-cause and cardiovascular mortality, we used the Cox regression model. The multivariable analysis showed that patients with potassium concentrations <3.5 mmol/L (hazard ratio (HR): 3.03; 95% CI: 2.49-3.70) and 3.5-4.0 mmol/L (HR: 1.81; 95% CI: 1.54-2.14) had a worse prognosis compared to the reference. We observed similar results when calculating the risk of cardiovascular mortality. A restricted cubic spline curve showed a U-shaped relationship between plasma-potassium and all-cause mortality. Patients with chronic HF and hyperkalaemia who became hypokalaemic after 6-30 days were associated with a higher 60-day all-cause and cardiovascular mortality compared to the reference. This also applied for patients with low normal potassium concentrations (3.5-4.0 mmol/L).

Sections du résumé

BACKGROUND/AIM OBJECTIVE
There is an increasing prevalence of chronic heart failure (HF). It is well known that patients with HF and disturbances in the potassium level have an increased mortality risk. The aim of this study was to investigate the prognosis of a second plasma-potassium measurement after an episode with hyperkalaemia on short-term mortality in patients with chronic HF.
METHODS AND RESULTS RESULTS
From Danish national registers, 2,339 patients with chronic HF and hyperkalaemia (>4.6 mmol/L) at first potassium measurement within 14-365 days from concomitant treatment were identified. To be included, a second measurement was required within 6-30 days subsequent to the first measurement and the 60-day mortality was observed. Based on the second measurement, the patients were divided into five groups: <3.5 mmol/L (n = 257), 3.5-4.0 mmol/L (n = 709), 4.1-4.6 mmol/L (n = 1,204, reference), 4.7-5.0 mmol/L (n = 89) and >5.0 mmol/L (n = 80). To assess all-cause and cardiovascular mortality, we used the Cox regression model. The multivariable analysis showed that patients with potassium concentrations <3.5 mmol/L (hazard ratio (HR): 3.03; 95% CI: 2.49-3.70) and 3.5-4.0 mmol/L (HR: 1.81; 95% CI: 1.54-2.14) had a worse prognosis compared to the reference. We observed similar results when calculating the risk of cardiovascular mortality. A restricted cubic spline curve showed a U-shaped relationship between plasma-potassium and all-cause mortality.
CONCLUSION CONCLUSIONS
Patients with chronic HF and hyperkalaemia who became hypokalaemic after 6-30 days were associated with a higher 60-day all-cause and cardiovascular mortality compared to the reference. This also applied for patients with low normal potassium concentrations (3.5-4.0 mmol/L).

Identifiants

pubmed: 37517938
pii: S0953-6205(23)00261-3
doi: 10.1016/j.ejim.2023.07.031
pii:
doi:

Substances chimiques

Potassium RWP5GA015D

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

82-88

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.

Auteurs

Sofie Solhøj Jønsson (SS)

Department of Health, Science, and Technology, Aalborg University, Aalborg, Denmark; Centre for Clinical Research, North Denmark Regional Hospital, Hjoerring, Denmark. Electronic address: s.joensson@rn.dk.

Sofie Amalie Sørensen (SA)

Department of Health, Science, and Technology, Aalborg University, Aalborg, Denmark; Centre for Clinical Research, North Denmark Regional Hospital, Hjoerring, Denmark.

Sidse Thim Krøgh (ST)

Department of Health, Science, and Technology, Aalborg University, Aalborg, Denmark; Centre for Clinical Research, North Denmark Regional Hospital, Hjoerring, Denmark.

Dorte Melgaard (D)

North Denmark Regional Hospital, Hjoerring, Denmark; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark; Mech-Sense, Department of Gastroenterology and Hepatology, Aalborg University Hospital, Aalborg, Denmark.

Peter Søgaard (P)

Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark.

Marc Meller Søndergaard (MM)

Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark.

Peter Leutscher (P)

Centre for Clinical Research, North Denmark Regional Hospital, Hjoerring, Denmark; North Denmark Regional Hospital, Hjoerring, Denmark.

Kristian Kragholm (K)

Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark.

Mette Aldahl (M)

Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark.

Christian Torp-Pedersen (C)

Department of Cardiology, Nordsjaellands Hospital, Hillerød, Denmark; Department of Public Health, University of Copenhagen, Denmark.

Maria Lukács Krogager (ML)

Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH